Y Intercept Hong Kong Ltd Acquires New Shares in Fractyl Health, Inc. $GUTS

Y Intercept Hong Kong Ltd acquired a new position in Fractyl Health, Inc. (NASDAQ:GUTS) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 111,425 shares of the company’s stock, valued at approximately $181,000.

Several other hedge funds and other institutional investors have also bought and sold shares of GUTS. Woodline Partners LP boosted its holdings in shares of Fractyl Health by 47.2% during the 1st quarter. Woodline Partners LP now owns 516,921 shares of the company’s stock valued at $615,000 after acquiring an additional 165,786 shares during the last quarter. HighTower Advisors LLC lifted its position in Fractyl Health by 57.9% during the first quarter. HighTower Advisors LLC now owns 40,921 shares of the company’s stock valued at $49,000 after purchasing an additional 15,000 shares during the period. Nuveen LLC purchased a new stake in Fractyl Health in the first quarter worth approximately $87,000. Chicago Partners Investment Group LLC bought a new stake in Fractyl Health in the 1st quarter worth approximately $37,000. Finally, Bank of New York Mellon Corp raised its stake in Fractyl Health by 54.5% during the 1st quarter. Bank of New York Mellon Corp now owns 64,020 shares of the company’s stock valued at $76,000 after buying an additional 22,572 shares during the last quarter.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the company. Canaccord Genuity Group dropped their price target on Fractyl Health from $12.00 to $6.00 and set a “buy” rating on the stock in a research note on Thursday, August 14th. LADENBURG THALM/SH SH initiated coverage on Fractyl Health in a report on Thursday, August 28th. They issued a “buy” rating and a $3.60 target price on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Fractyl Health in a research report on Wednesday, October 8th. Finally, HC Wainwright reduced their price target on shares of Fractyl Health from $9.00 to $8.00 and set a “buy” rating for the company in a research report on Friday, September 26th. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Fractyl Health currently has an average rating of “Moderate Buy” and an average price target of $6.90.

Fractyl Health Price Performance

NASDAQ GUTS opened at $1.10 on Monday. The company has a market capitalization of $55.32 million, a PE ratio of -0.53 and a beta of 2.21. The company has a debt-to-equity ratio of 4.61, a quick ratio of 1.22 and a current ratio of 1.22. The business’s fifty day moving average is $1.20 and its 200 day moving average is $1.47. Fractyl Health, Inc. has a fifty-two week low of $0.83 and a fifty-two week high of $3.03.

Fractyl Health (NASDAQ:GUTS) last issued its quarterly earnings results on Tuesday, August 12th. The company reported ($0.53) EPS for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.16). Sell-side analysts predict that Fractyl Health, Inc. will post -1.61 earnings per share for the current year.

Fractyl Health Company Profile

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.